Volition Appoints Timothy I. Still as Chairman

Core Insights - VolitionRx Limited has appointed Timothy Still as Chairman of its board of directors, effective November 6, 2024, bringing over 35 years of experience in medical diagnostics and digital health [1][2][3] Company Overview - Volition is a multi-national company focused on advancing the science of epigenetics, dedicated to improving outcomes for people and animals through earlier detection and monitoring of life-altering diseases [5][6] - The company is developing simple, cost-effective blood tests aimed at diagnosing and monitoring various diseases, including cancers and conditions associated with NETosis, such as sepsis [6][4] Leadership and Experience - Timothy Still has held significant leadership roles in various medical technology companies, including President and CEO of Sense Biodetection, and has a strong track record in guiding companies from R&D to market readiness [2][3] - Cameron Reynolds, President and Group CEO of Volition, expressed enthusiasm about Still's appointment, highlighting his extensive experience in the diagnostic sector [3] Strategic Vision - Timothy Still emphasized the potential of Volition's epigenetic technology to significantly impact global healthcare by improving disease detection and treatment monitoring [3] - The company aims to leverage Still's strategic advice and leadership to drive its next phase of growth [3]